Trail­ing GSK, As­traZeneca of­fers an en­cour­ag­ing look at PhI­II da­ta for three-in-one COPD in­haler

As­traZeneca $AZN start­ed the day with news that its three-in-one chron­ic ob­struc­tive pul­monary dis­ease in­haler has turned out pos­i­tive top-line re­sults in a Phase III tri­al. But they may have ar­rived too late with too lit­tle to di­rect­ly chal­lenge Glax­o­SmithK­line in the field.

Com­pared with dual com­bi­na­tion ther­a­pies, twice-dai­ly dos­es of PT010 — which con­tains budes­onide, gly­copy­rro­ni­um and for­moterol fu­marate — demon­strat­ed sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment in eight out of nine lung func­tion pri­ma­ry end­points, the UK phar­ma gi­ant said, with­out pro­vid­ing num­bers. A for­mu­la­tion of gly­copy­rro­ni­um and for­moterol fu­marate makes Bevespi Aeros­phere, cur­rent­ly ap­proved for COPD.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.